COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04927065

Not reported

Not reported

2021-06-15

Completed

nonRCT

Non-randomized

Sequential assignment

Open label

multi-center

Prevention

key inclusion criteria: for female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to day 1, agreement to continue adequate contraception or abstinence through 3 months following the vaccination, and not currently breastfeeding. participants must have been either previously enrolled in the mrna-1273-p301 (cove) study, must have received 2 doses of mrna-1273 in that study, with their second dose at least 6 months prior to enrollment in this study (mrna-1273-p205), and must be currently enrolled and compliant in that study (that is, has not withdrawn or discontinued early); or participant must have received 2 doses of mrna-1273 under the eua with their second dose at least 6 months prior to enrollment in mrna-1273-p205; or have received a 2 dose primary series of mrna-1273 followed by a 50 μg booster dose of mrna-1273 in the mrna-1273-p301 (cove) study or under eua at least 3 months prior to enrolment in mrna-1273-p205; and able to provide proof of vaccination status at the time of screening (day 1); or for enrollment in part a.2, participant must be currently enrolled and compliant in part a.1 of the mrna 1273 p205 study and must have received their first booster dose of mrna 1273.211 50 μg; or for enrollment in part j, participant must meet at least 1 of the following criteria: completed enrollment in part h of the mrna-1273-p205 study; or received a 2-dose primary series of mrna-1273 (100 μg) followed by a 50 μg booster dose of mrna-1273 in the mrna-1273-p301 (cove) study or under eua, followed by a 50 μg booster dose of mrna-1273.222 under eua at least 3 months prior to enrollment in part j of mrna-1273-p205; or previously received a 2-dose primary series of mrna vaccine against sars-cov-2 followed by a booster dose of a monovalent mrna vaccine, followed by a second booster dose of a bivalent mrna vaccine. participants in part j must also provide proof of vaccination status at the time of screening (day 0 or day 1). key

significant exposure to someone with sars-cov-2 infection or covid-19 in the past 14 days, as defined by the us centers for disease control and prevention (cdc) as a close contact of someone who has had covid-19. known history of sars-cov-2 infection within 3 months prior to enrollment. is acutely ill or febrile (temperature ≥38.0°celsius/[100.4°fahrenheit]) less than 72 hours prior to or at the screening visit (day 0) or day 1. has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment. has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to screening (for corticosteroids ≥10 milligrams (mg)/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. known or suspected allergy or history of anaphylaxis, urticaria, or other significant ar to the vaccine or its excipients. has a documented history of myocarditis or pericarditis within 2 months prior to screening visit (day 0). has received or plans to receive any licensed vaccine ≤28 days prior to the injection (day 1) or a licensed vaccine within 28 days before or after they study injection, with the exception of influenza vaccines, which may be given 14 days before or after receipt of a study vaccine. has received systemic immunoglobulins or blood products within 3 months prior to the screening visit (day 0) or plans for receipt during the study. has donated ≥450 milliliters (ml) of blood products within 28 days prior to the screening visit (day 0) or plans to donate blood products during the study. is currently experiencing an sae in study mrna-1273-p301 (cove) at the time of screening for this study. note: other inclusion and exclusion criteria may apply.

14

ModernaTX, Inc.

18

100

United States

Healthy volunteers

N/A

5404

Geometric mean fold rise (GMFR) of Omicron-Specific Antibody (For Part J only) at Day 15;Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody at Day 29;GMT of Omicron-Specific Antibody at Day 91 (For Part G only);GMT of Omicron-Specific Antibody (For Part J only) at Day 15;GMT of Omicron-Specific Antibody (For Parts F, G, H and J only) at Day 29;GMT of SARS-CoV-2-Specific Antibody at Day 91 (For Part G only);Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs);Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients at Day 15 (For Part J only);Seroresponse Rate of Vaccine Recipients at Day 29;Seroresponse Rate of Vaccine Recipients at Day 91 (For Part G only)

None

Phase 2/Phase 3

[{"arm_notes": "Part A.1: mRNA-1273.211 50 \u03bcg", "treatment_id": 825, "treatment_name": "Mrna-1273.211", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part A.1: mRNA-1273.211 100 \u03bcg", "treatment_id": 825, "treatment_name": "Mrna-1273.211", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part B: mRNA-1273 100 \u03bcg", "treatment_id": 824, "treatment_name": "Mrna-1273", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part C: mRNA-1273.617.2 100 \u03bcg", "treatment_id": 2035, "treatment_name": "Mrna-1273.617.2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part C: mRNA-1273.617.2 50 \u03bcg", "treatment_id": 2035, "treatment_name": "Mrna-1273.617.2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part D: mRNA-1273.213 50 \u03bcg", "treatment_id": 2036, "treatment_name": "Mrna-1273.213", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part D: mRNA-1273.213 100 \u03bcg", "treatment_id": 2036, "treatment_name": "Mrna-1273.213", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part E: mRNA-1273.213 100 \u03bcg", "treatment_id": 2036, "treatment_name": "Mrna-1273.213", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part F Cohort 1: mRNA-1273.529 50 \u03bcg", "treatment_id": 2176, "treatment_name": "Mrna-1273.529", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part F Cohort 2: mRNA-1273.529 50 \u03bcg and mRNA-1273 50 \u03bcg", "treatment_id": 2392, "treatment_name": "Mrna-1273+mrna-1273.529", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part G: mRNA-1273.214 50 \u03bcg", "treatment_id": 2441, "treatment_name": "Mrna-1273.214", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part A.2: mRNA-1273.214 50 \u03bcg", "treatment_id": 2441, "treatment_name": "Mrna-1273.214", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part H: mRNA-1273.222 50 \u03bcg", "treatment_id": 2605, "treatment_name": "Mrna-1273.222", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part J: mRNA-1273.815 or mRNA-1273.231", "treatment_id": 2733, "treatment_name": "Mrna-1273.231+mrna-1273.815", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]